Matthew J. Matasar, MD, Discusses ‘Breadth of Scientific Investigation’ at AACR Annual Meeting

Video

The lymphoma expert offered highlights from the meeting, with hopes that more treatment options will be available for patients with lymphoma.

Week 1 of the Virtual American Association for Cancer Research (AACR) 2021 Annual Meeting offered a variety of data on trials ranging from preclinical to phase 3 studies. In particular, Matthew J. Matasar, MD, is excited most about the presentations surrounding chromosomal instability in cancer.

Matasar, associate member of Lymphoma Service, Department of Medicine, at Memorial Sloan Kettering Cancer Center, spoke with CancerNetwork® about his hopes for future treatments coming out of the meeting.

Transcription:

I think AACR, for me, really brings home the breadth of scientific investigation that’ s being applied to such patients and their illnesses. And I really see the future landscape of this set of illnesses as being one in which we’re going to have more effective and less toxic treatments for our patients.

[There’s] just a tremendous breadth of scientific inquiry that’s been presented this year. I’ve been particularly interested in the story of the chromosomal instability and found the work that was presented, looking at that and documenting how this works and the clinical implications of this is really being very provocative.

Reference:

Matasar MJ, Capra M, Ozcan M, et al. CHRONOS-3: randomized phase III study of copanlisib plus rituximab vs rituximab/placebo in relapsed indolent non-Hodgkin lymphoma (iNHL). Presented at: 2021 AACR Annual Meeting 2021; April 10-15, 2021; virtual. Abstract CT001.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content